Your browser doesn't support javascript.
loading
Prolactin excess: treatment and toxicity.
Gillam, Mary P; Fideleff, Hugo; Boquete, Hugo R; Molitch, Mark E.
Afiliação
  • Gillam MP; Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA, and Endocrinology Unit, Alvarez Hospital, Buenos Aires, Argentina.
Pediatr Endocrinol Rev ; 2 Suppl 1: 108-14, 2004 Nov.
Article em En | MEDLINE | ID: mdl-16456489
ABSTRACT
Dopamine agonists provide highly effective therapy for the treatment of hyperprolactinemia. As a result of their efficacy and tolerability, these agents are considered to be the initial therapy of choice in children, adolescents and adults with idiopathic hyperprolactinemia and prolactinomas. The four dopamine agonists, bromocriptine, pergolide, cabergoline and quinagolide, share a similar mechanism of action and side effect profile. Although studies of cabergoline have demonstrated the highest treatment efficacy and tolerability, all four of these agents are safe, effective and tolerable in children and adolescents. When fertility is desired, bromocriptine is generally preferable, but cabergoline is also likely safe; pergolide and quinagolide should not be used in this setting.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Neoplasias Hipofisárias / Hiperprolactinemia / Prolactinoma / Agonistas de Dopamina Idioma: En Ano de publicação: 2004 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Neoplasias Hipofisárias / Hiperprolactinemia / Prolactinoma / Agonistas de Dopamina Idioma: En Ano de publicação: 2004 Tipo de documento: Article